Expert Interview
A Second Opinion: Discussing the potential of Kiniksa's KPL-404 and Aclaris's zunsemetinib (ATI-450) for treatment of patients with rheumatoid arthritis
Ticker(s): KNSA, ACRSInstitution: University of Pittsburgh Medical Center
- Assistant Professor of Medicine and Staff Rheumatologist-University of Pittsburgh Medical Center.
- Manages 180 patients with rheumatoid arthritis, 50 patients with Systemic Lupus Erythematosus
- Research interests include inflammatory myopathies and biomarker clinical studies.
What potential readthrough to RA is there from the Phase 2a trial of '450 in Hidradenitis Suppurativa that did not achieve its primary or secondary endpoints?
Added By: madsteerGiven ' 450's mechanism of action targeting the p38-MK2 complex and data to date, what is your level of conviction regarding the mechanistic rationale in RA?
Added By: madsteerIn your view, what are the unmet needs in RA, and where do these two pipeline drugs potentially fit into addressing these unmet needs?
Added By: madsteerIn terms of efficacy, what thresholds would you be looking for coming into the upcoming readouts for both KPL-404 and ATI-450?
Added By: madsteerFrom data to date, are there any safety / tolerability signals that concern you? Specifically for '450, there was some evidence of CPK elevation in the recent HS Ph2a trial - what do you read into this? Is there anything to be learned from CPK elevation experience with JAKis?
Added By: madsteerAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
